Gland Pharma : Recording of Analysts/Institutional Investor Meet/Con. Call
November 29, 2022 at 10:09 pm EST
Share
November 29, 2022
BSE Limited
National Stock Exchange of India Limited
Corporate Relationship Department
Listing Department
Phiroze Jeejeebhoy Towers
Exchange Plaza, 5th floor
25th floor, Dalal Street
Plot no. C-1, Block G, Bandra Kurla Complex
Mumbai - 400 001
Bandra (East), Mumbai - 400 051
Scrip Code: 543245
Symbol: GLAND (ISIN: INE068V01023)
Dear Sir/Madam,
Sub: Investor Call Recording
Pursuant to Regulations 30 and 46 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015; please note that the Investor Call regarding the proposed acquisition of Cenexi Group, was held on November 29, 2022 at 19:00 Hrs. (IST) and the audio recording of the call has been uploaded on our website.
The weblink to access the same ishttps://glandpharma.com/images/Gland audio file.mp3
This is for your information and records.
Yours truly,
For Gland Pharma Limited
SAMPATH
KUMAR
PALLERLAMUDI
Digitally signed by SAMPATH KUMAR PALLERLAMUDI DN: cn=SAMPATH KUMAR PALLERLAMUDI, c=IN, o=Personal, email=sampath@glandpharma.com Date: 2022.11.29 23:42:48 +05'30'
P Sampath Kumar
Company Secretary and Compliance Officer
Attachments
Original Link
Original Document
Permalink
Disclaimer
Gland Pharma Ltd. published this content on 29 November 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 30 November 2022 03:02:13 UTC.
Gland Pharma Limited is an India-based generic injectables manufacturer. The Company specializes in sterile injectables, oncology, and ophthalmic, with a specific focus on complex injectables, NCE-1s (New Chemical Entities), First-to-File products, and 505(b)(2) filings. The Company functions primarily on a business-to-business (B2B) model and has a record in pharmaceutical research and development, manufacturing, and marketing of complex injectables. The Company offers a range of delivery systems, including liquid vials, lyophilized vials, pre-filled syringes, ampoules, bags, and drops. It is also in the process of including new delivery systems such as pens and cartridges into its product portfolio. Its key molecules include Heparin Sodium Injection, Enoxaparin Sodium Injection, Rocuronium Bromide Injection, Daptomycin Injection, among others. Its therapeutic products categories include Anti Malarials, Anti-Infectives, Anti-Neoplastics, Gynaecological, Hormones, and others.
GLAND PHARMA LIMITED 
